- Home
- TGTX vs QTWO Comparison
TGTX vs QTWO Comparison
Compare TGTX & QTWO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- QTWO
- Stock Information
- Founded
- TGTX 1993
- QTWO 2004
- Country
- TGTX United States
- QTWO United States
- Employees
- TGTX N/A
- QTWO N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- QTWO Computer Software: Prepackaged Software
- Sector
- TGTX Health Care
- QTWO Technology
- Exchange
- TGTX Nasdaq
- QTWO Nasdaq
- Market Cap
- TGTX 4.2B
- QTWO 4.7B
- IPO Year
- TGTX 1995
- QTWO 2014
- Fundamental
- Price
- TGTX $29.45
- QTWO $79.52
- Analyst Decision
- TGTX Strong Buy
- QTWO Buy
- Analyst Count
- TGTX 4
- QTWO 17
- Target Price
- TGTX $42.50
- QTWO $103.50
- AVG Volume (30 Days)
- TGTX 2.9M
- QTWO 1.0M
- Earning Date
- TGTX 08-04-2025
- QTWO 07-30-2025
- Dividend Yield
- TGTX N/A
- QTWO N/A
- EPS Growth
- TGTX N/A
- QTWO N/A
- EPS
- TGTX 0.36
- QTWO 0.07
- Revenue
- TGTX $454,069,000.00
- QTWO $742,949,000.00
- Revenue This Year
- TGTX $84.00
- QTWO $14.42
- Revenue Next Year
- TGTX $39.26
- QTWO $10.67
- P/E Ratio
- TGTX $81.62
- QTWO $1,084.50
- Revenue Growth
- TGTX 30.96
- QTWO 13.34
- 52 Week Low
- TGTX $21.11
- QTWO $63.61
- 52 Week High
- TGTX $46.48
- QTWO $112.82
- Technical
- Relative Strength Index (RSI)
- TGTX 42.03
- QTWO 48.38
- Support Level
- TGTX $27.23
- QTWO $74.63
- Resistance Level
- TGTX $28.85
- QTWO $76.07
- Average True Range (ATR)
- TGTX 1.11
- QTWO 1.96
- MACD
- TGTX 0.29
- QTWO 0.58
- Stochastic Oscillator
- TGTX 99.05
- QTWO 90.96
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About QTWO Q2 Holdings Inc.
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.